Newly Diagnosed HF and the Role of the Wearable Cardioverter Defibrillator

Published: 26 May 2023

  • Views:

    Views Icon 1626
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

Dr Luca Santini (G. B. GRASSI Hospital, Italy) focused on the role of the wearable cardioverter defibrillator (WCD) during the high-risk phase in HF-patients. He concludes that the high-risk phase of HF poses a considerable threat of SCD, necessitating temporary protection strategies. A WCD can offer a valuable solution by providing continuous monitoring and the ability to deliver life-saving shocks when dangerous arrhythmias are detected.

This content is sponsored by ZOLL


You must be to comment. If you are not registered, you can register here.